Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037]
Corresponding Author of This Article
Bin Song, MD, Chief Doctor, Director, Professor, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. cjr.songbin@vip.163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 14, 2021; 27(22): 3037-3049 Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.3037
Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
Yun Zhang, Zi-Xing Huang, Bin Song
Yun Zhang, Zi-Xing Huang, Bin Song, Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhang Y and Song B designed the research; Zhang Y and Huang ZX conducted literature search and analysis; Huang ZX and Song B provided material support and revised and proofread the paper; Huang ZX and Song B contributed equally to this work.
Conflict-of-interest statement: The authors have nothing to disclose regarding this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Song, MD, Chief Doctor, Director, Professor, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. cjr.songbin@vip.163.com
Received: January 27, 2021 Peer-review started: January 27, 2021 First decision: February 25, 2021 Revised: March 8, 2021 Accepted: April 26, 2021 Article in press: April 26, 2021 Published online: June 14, 2021 Processing time: 132 Days and 7.9 Hours
Core Tip
Core Tip: The timely and accurate evaluation of tumor response in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) is of great significance to increase the probability of tumor R0 resection and prolong survival. Ultrasound and conventional computed tomography imaging features show limited roles in the evaluation of NAT response for PDAC. Novel imaging biomarkers extracted from functional imaging technologies show promise in providing further important information for the assessment of tumor resectability and survival prediction. We reviewed the application and value of NAT in PDAC, as well as the advantages, limitations, and future development directions of current imaging techniques in tumor response assessment of PDAC after NAT in this article.
